A Phase II Study of Topotecan with Vincristine and Doxorubicin in Children with Recurrent/Refractory Neuroblastoma

Cancer

Volumn 98, Issue 11, 2003, Pages 2488-2494

  Garaventa, Alberto ^a   Luksch, Roberto ^b   Biasotti, Simona ^a   Severi, Gianluca ^c   Pizzitola, Maria Rosa ^a   Viscardi, Elisabetta ^d   Prete, Arcangelo ^e   Mastrangelo, Stefano ^f   Podda, Marta ^b   Haupt, Riccardo ^a   De Bernardi, Bruno ^a  

^a G GASLINI INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Doxorubicin; Neuroblastoma; Phase II; Topotecan; Vincristine

Indexed keywords

AMINOTRANSFERASE; ANTIBIOTIC AGENT; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEREMIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEMALE; FEVER; HEMATOLOGIC TOXICITY; HEMATOPOIETIC SYSTEM; HEMATURIA; HUMAN; INFECTION; INSTITUTIONAL CARE; ITALY; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NONHEMATOLOGIC TOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; REFRACTORY PERIOD; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TUMOR GROWTH; VIRUS INFECTION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME; VINCRISTINE;

EID: 0344844485     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11797     Document Type: Article

References (33)

1. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in Stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998;16:953-965.
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
3. Kollmannsberger C, Mross K, Jakob A, et al. Topotecan a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56:1-12.
4. Vassal G, Pondarré C, Cappelli C, et al. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer. 1997;33:2011-2015.
5. Houghton PJ, Cheshire PJ, Myers L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 1992;31:229-239.
6. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Nad Cancer Inst. 1998;90:505-511.
7. Rewinsky K, Verweij J. Review of Phase I clinical studies with topotecan. Semin Oncol. 1998;24:3-20.
8. McGuire P, William P, Blessing JA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2000;18:1062-1067.
9. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 1996;18:352-361.
10. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J Clin Oncol. 2001;19:3463-3469.
11. Rowinsky EK, Kaufmann SH. Topotecan in combination chemotherapy. Semin Oncol. 1997;24(6 Suppl 20):S20-11-S20-26.
12. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer. 1992;50:760-766.
13. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999;5:3617-3631.
14. Helson L, Groshen S, Castello MA, et al. Constant infusion vincristine-Adriamycin in pediatric cancer [abstract]. XVII Meeting of the International Society of Pediatric Oncology, Venice, Italy, September 30-October 4, 1985.
15. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda: National Cancer Institute, 1998.
16. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment. J Clin Oncol. 1993;11:1466-1477.
17. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage Phase II clinical trials. Biometrics. 1995;51:1372-1383.
18. Kushner BH, Kramer K, Meyers PA, et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol. 2000;35:468-474.
19. Wells RJ, Reid JM, Ames MM, et al. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol. 2002;24:89-93.
20. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002;20:88-95.
21. Cheung MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994;6:269-279.
22. Jonsson E, Fridborg H, Nygren P. Synergistic interactions of combination of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998;54:509-514.
23. Murren JR, Anderson S, Fedele J, et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J Clin Oncol. 1997;15:148-157.
24. Seiden MV, Ng SW, Supko JG, et al. A Phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res. 2002;8:691-697.
25. Goldwasser F, Buthaud X, Gross M. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anticancer Drugs. 1999;10:263-265.
26. Frappaz D, Michon J, Hartmann O, et al. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology Phase II study. J Clin Oncol. 1992;10:1592-1601.
27. Meresse V, Vassal G, Michon J, et al. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a Phase II study from the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1993;11:630-637.
28. Alvarado CS, Kretschmar C, Joshi VV, et al. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study. J Pediatr Hematol Oncol. 1997;19:62-67.
29. Frappaz D, Bouffet E, Perel Y, et al. Phase II study of cis-platinum and carboplatinum (CACIS) combination in advanced stage neuroblastomas. Med Pediatr Oncol. 1998;30:9-14.
30. McWilliams NB, Hayes FA, Green AA, et al. Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study. Med Pediatr Oncol. 1995;24:176-180.
31. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis. Comparable results with three consecutive high-dose protocols adopted by the Italian Cooperative Group for Neuroblastoma (ICGNB). J Clin Oncol. 2003;21:1592-1601.
32. Kretschmar C, Kletzel M, Murray K, et al. Up-front Phase II therapy with Taxol and topotecan in untreated children with disseminated neuroblastoma. A Pediatric Oncology Group study (SIOP XXVII Meeting) [abstract]. Med Pediatr Oncol. 1995;25:243.
33. Pearson AD, Pinkerton CR, Levis IJ. European Neuroblastoma Group Fifth Study (ENSG 5). A randomised study of dose intensity in Stage 4 neuroblastoma over the age of one. In: Evans AE, Biedler JL, Brodeur GM, D'Angio GJ, Nakagawara A, editors. Progress in clinical and biological research-advances in neuroblastoma research. New York: Wiley-Liss, 1994:385-394.